Company profile
EUPRAXIA PHARMACEUTICALS INC.
NASDAQ:EPRXPharmaceuticals and Biotechnology
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05608681 | phase1_2 | recruiting | 2023-03-31 | 2026-12-01 | Eupraxia Pharmaceuticals Inc. | A Trial to Evaluate EP-104GI in Adults With Eosinophilic Esophagitis (EoE). |
| NCT02609126 | phase1 | completed | 2016-04-01 | 2017-12-28 | Eupraxia Pharmaceuticals Inc. | Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis |
| NCT04120402 | phase2 | completed | 2021-09-10 | 2023-05-17 | Eupraxia Pharmaceuticals Inc. | Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee |
FDA applications (0)
No records yet.